Ananda S Bandyopadhyay Selected Research

Poliomyelitis (Polio)

6/2022	Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021.
3/2022	Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience.
1/2022	Mucosal immunity to poliovirus.
1/2022	Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa.
12/2021	Multiscale model for forecasting Sabin 2 vaccine virus household and community transmission.
9/2021	Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic.
6/2021	Safeguarding vaccine production and supply strategies for polio eradication endgame.
1/2021	Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
1/2021	Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication.
1/2021	A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ananda S Bandyopadhyay Research Topics

Disease

31	Poliomyelitis (Polio) 06/2022 - 01/2015
3	Infections 01/2019 - 12/2016
2	acute flaccid myelitis 06/2022 - 01/2018
2	Paralysis (Palsy) 02/2022 - 01/2022
1	COVID-19 09/2021
1	Hypersensitivity (Allergy) 01/2021
1	Blister (Bulla) 09/2017
1	Rubella (German Measles) 01/2016
1	Yellow Fever 01/2016
1	Measles 01/2016
1	Intussusception 11/2015

Drug/Important Bio-Agent (IBA)

30	VaccinesIBA 06/2022 - 01/2015
11	Oral Poliovirus Vaccine (Sabin Vaccine)IBA 01/2022 - 11/2015
8	Inactivated Poliovirus Vaccine (Salk Vaccine)FDA Link 01/2021 - 11/2015
3	Immunoglobulin A (IgA)IBA 01/2019 - 01/2018
2	Poliovirus VaccinesIBA 01/2022 - 01/2021
2	Neutralizing AntibodiesIBA 01/2021 - 12/2017
2	hydroxide ionIBA 01/2020 - 01/2017
2	AluminumIBA 01/2020 - 01/2017
2	Combined VaccinesIBA 10/2018 - 01/2016
2	AntibodiesIBA 10/2018 - 12/2016
1	5' Untranslated Regions (5' UTR)IBA 02/2022
1	dimethylaminonaphthalene- 5- sulfonaminoethylmethylamine (DDNS)IBA 01/2022
1	pocapavirIBA 01/2019
1	Antiviral Agents (Antivirals)IBA 01/2019
1	AntigensIBA 01/2018
1	Viral ProteinsIBA 01/2018
1	Yellow Fever Vaccine (Vaccine, Yellow Fever)FDA Link 01/2016